Introduce Tixagev/Cilgavim in Muscle, Perc, New Tech 7

This code describes the administration of a specific combination of monoclonal antibodies, tixagevimab and cilgavimab, directly into muscle tissue. This intervention is performed through the skin using a needle, without requiring an incision. It represents a novel therapeutic approach for certain conditions.

This code is used when a patient receives tixagevimab and cilgavimab via intramuscular injection for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals or those for whom COVID-19 vaccination is not recommended. It applies to inpatient encounters where this specific monoclonal antibody combination is administered.

• Verify that both tixagevimab and cilgavimab were administered together.
• Confirm the administration route was intramuscular (into muscle) and percutaneous.
• This code is for the introduction of the substance, not the substance itself.